XERS – xeris biopharma holdings, inc. (US:NASDAQ)
Stock Stats
News
Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? [Yahoo! Finance]
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
Form 144 Xeris Biopharma Holdings Filed by: BORMANN-KENNEDY BARBARA-JEAN ANNE
Form 4 Xeris Biopharma Holdings For: Dec 01 Filed by: Hecht Beth
Form 8-K Xeris Biopharma Holdings For: Dec 01
Form 4 Xeris Biopharma Holdings For: Nov 13 Filed by: Shannon John Patrick Jr
Form 4 Xeris Biopharma Holdings For: Nov 11 Filed by: Hecht Beth
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.